GHRP-6 vs Hexarelin

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a mechanism that is synergistic with but distinct from endogenous growth hormone-releasing hormone (GHRH). Like other GHRP-class peptides, it engages hypothalamic arcuate nucleus circuits to potentiate GHRH-driven GH pulses and partially suppress somatostatin inhibitory tone; it was among the first GHRP-class compounds characterized pharmacologically and has been used extensively as a research tool for probing the GH secretory axis. Clinical studies have demonstrated dose-dependent GH release following GHRP-6 administration in human subjects, and the GHRP pharmacological class has been characterized across multiple studies documenting pituitary and hypothalamic mechanisms of action. GHRP-6 is not FDA-approved for any indication; it has been studied as a pharmacological tool and provocative GH stimulation agent but has not been evaluated for safety or efficacy in performance enhancement or muscle building outside research protocols. GHRP-6 dosage in research contexts: studies have used subcutaneous and intravenous doses typically in the range of 100–300 mcg per injection. In research protocols, GHRP-6 is often administered 2–3 times daily — before meals, before training, or before sleep — to leverage the body's natural GH pulse windows. GHRP-6 produces a pronounced appetite stimulation effect (a direct ghrelin-mimetic consequence) that is stronger than what is observed with more selective GHRPs such as ipamorelin; this characteristic is relevant to research contexts studying GH secretion alongside energy intake regulation. GHRP-6 vs GHRP-2: both are non-selective GHRPs producing GH alongside cortisol and prolactin co-stimulation, but GHRP-6 is noted for more pronounced ghrelin-like appetite stimulation, while GHRP-2 produces greater GH output per unit dose in some comparative studies. Neither offers the selectivity profile of ipamorelin, which emerged from subsequent GHRP research specifically to reduce off-target hormonal effects. GHRP-6 is administered by subcutaneous injection following reconstitution with bacteriostatic water. Providers offering GHRP-class secretagogues are listed in the PeptideBase directory.

Potent synthetic GHRP; strongest GH secretagogue in its class; also activates CD36 scavenger receptor for cardioprotective effects

Hexarelin is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) and is among the most potent GHRP-class peptides characterized in human studies, producing robust GH release at low doses via a mechanism that synergizes with endogenous GHRH and partially suppresses somatostatin. In addition to its pituitary GHS-R1a effects, hexarelin has been shown to engage CD36 receptor-mediated pathways in cardiac tissue, suggesting biological activity beyond GH secretion, though the cardiac pharmacology has not been developed into an approved clinical application. Human endocrine studies have directly compared hexarelin-induced GH release with ghrelin and GHRH in healthy volunteers, confirming its potent pituitary activity; repeated administration produces progressive attenuation of the GH response consistent with receptor desensitization. Hexarelin is not FDA-approved for any indication; it is used as a research tool for characterizing the GH secretagogue receptor system and has not been evaluated for safety or efficacy in performance enhancement contexts. Research interest in hexarelin centers on two distinct biological roles: its potent GH-secreting activity — relevant to muscle recovery and body composition research contexts — and its cardiac tissue effects via CD36 receptor pathways, which distinguish it mechanistically from simpler GHRPs such as GHRP-2 and GHRP-6. Hexarelin dosage in research contexts: published human studies have used intravenous doses of 1–2 mcg/kg to characterize GH secretion kinetics. In clinical research protocols, subcutaneous doses of 100–200 mcg per injection are most commonly cited, typically administered once or twice daily. Hexarelin's potency relative to other GHRPs means lower doses are required for equivalent GH stimulation; however, receptor desensitization with repeated dosing is more pronounced than with selective peptides such as ipamorelin, which has driven research interest in cycling protocols and combination approaches. Administration is by subcutaneous injection. Hexarelin vs ipamorelin: the two peptides differ substantially in selectivity and desensitization profile. Hexarelin is a non-selective GHRP that stimulates GH alongside modest elevations in cortisol, prolactin, and ACTH — effects documented in human challenge studies. Ipamorelin, by contrast, is one of the most selective GHRPs characterized, producing GH secretion with minimal cortisol or prolactin co-stimulation. For research focused specifically on GH secretion with a cleaner hormonal background, ipamorelin is generally preferred; hexarelin is studied in contexts where its dual CD36/GHS-R1a pharmacology is the research focus. Providers offering hexarelin are listed in the PeptideBase directory.